Healthcare / BiotechnologyNasdaqCM
$0.68
-0.03 (-4.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-20.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
10347.6%
↑Gross Margin
-6.3%
↓Debt/Equity
-26.80
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+32.0%
FCF CAGR
—
FCF margin
-353.9%
FCF / Net income
1.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.9M · net income $-8.5M · FCF $-13.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.9M | $3.9M | $5.6M | $3.0M | $1.7M |
| Net Income | $-8.5M | $-8.5M | $-16.5M | $-23.9M | $-26.6M |
| EBITDA | $-12.2M | $-12.2M | $-13.4M | $-20.5M | $-27.0M |
| EPS | -1.08 | -1.08 | -2.89 | -5.20 | -6.50 |
| Gross Margin | -6.3% | -6.3% | 57.3% | 50.0% | 45.7% |
| Operating Margin | -364.2% | -364.2% | -337.2% | -745.5% | -1608.4% |
| Net Margin | -220.2% | -220.2% | -295.6% | -800.8% | -1590.3% |
| Balance Sheet | |||||
| Debt/Equity | -26.80 | -26.80 | -8.87 | 0.95 | 0.43 |
| Current Ratio | 2.79 | 2.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.6M | $-13.6M | $-20.3M | $-22.2M | $-24.8M |
| Returns | |||||
| ROE | 10347.6% | 10347.6% | 1136.1% | -198.1% | -95.4% |
| Valuation | |||||
| P/B | — | — | — | 3.64 | 1.11 |
| Growth & Yield | |||||
| Revenue Growth | -30.9% | -30.9% | 87.0% | 78.0% | — |
| EPS Growth | 62.6% | 62.6% | 44.4% | 20.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.89 → -1.08
Residual
-37.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.